IN2013MN01519A - - Google Patents

Download PDF

Info

Publication number: IN2013MN01519A
Authority: IN; India
Prior art keywords: pharmaceutically acceptable; acceptable salt; diaminopyrimidine derivative; delayed; gastroparesis
Prior art date: 2011-02-25

Application number

Other languages

English (en)

Inventor

Hyun Joo Lee

Dong Hoon Kim

Tae Kyun Kim

Young Ae Yoon

Jae Young Sim

Myung Hun Cha

Eun Jung Jung

Kyoung Kyu Ahn

Tai Au Lee

Original Assignee

Yuhan Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-25

Filing date

2012-02-24

Publication date

2015-06-12

2012-02-24 Application filed by Yuhan Corp filed Critical Yuhan Corp

2015-06-12 Publication of IN2013MN01519A publication Critical patent/IN2013MN01519A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IN1519MUN2013 2011-02-25 2012-02-24 IN2013MN01519A (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20110016981		2011-02-25
PCT/KR2012/001423 WO2012115478A2 (en)	2011-02-25	2012-02-24	Diaminopyrimidine derivatives and processes for the preparation thereof

Publications (1)

Publication Number	Publication Date
IN2013MN01519A true IN2013MN01519A (ko)	2015-06-12

Family

ID=46721361

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN1519MUN2013 IN2013MN01519A (ko)	2011-02-25	2012-02-24

Country Status (18)

Country	Link
US (4)	US9850227B2 (ko)
EP (2)	EP2678331B1 (ko)
JP (2)	JP5890436B2 (ko)
KR (2)	KR101671348B1 (ko)
CN (2)	CN103391935B (ko)
AU (2)	AU2012221925B2 (ko)
BR (2)	BR112013020641B1 (ko)
CA (2)	CA2827030C (ko)
DK (1)	DK2678332T3 (ko)
ES (2)	ES2579830T3 (ko)
HK (2)	HK1188214A1 (ko)
HU (1)	HUE029988T2 (ko)
IN (1)	IN2013MN01519A (ko)
MX (2)	MX336155B (ko)
PL (2)	PL2678331T3 (ko)
PT (1)	PT2678332T (ko)
RU (1)	RU2587493C2 (ko)
WO (2)	WO2012115480A2 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX336155B (es) *	2011-02-25	2016-01-07	Yuhan Corp	Derivados de diaminopirimidina y procesos para su preparacion.
MX2015006469A (es)	2012-11-21	2015-10-29	Ptc Therapeutics Inc	Inhibidores de bmi-1 de pirimidina inversa sustituida.
KR101657616B1 (ko) *	2013-05-24	2016-09-19	주식회사유한양행	피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
TWI692477B (zh) *	2013-08-30	2020-05-01	美商Ｐｔｃ治療公司	經取代嘧啶ｂｍｉ-１抑制劑
EP3071553A4 (en)	2013-11-21	2017-08-02	PTC Therapeutics, Inc.	Substituted pyridine and pyrazine bmi-1 inhibitors
CN104003944B (zh) *	2014-05-29	2016-08-24	西北师范大学	一种嘧菌胺的制备方法
SI3604294T1 (sl) *	2014-10-13	2021-08-31	Yuhan Corporation	Spojine in sestavki za moduliranje aktivnosti kinaze mutanta EGFR
US10300155B2 (en)	2015-12-31	2019-05-28	Washington University	Alpha-synuclein ligands
CN105646321A (zh) *	2016-01-07	2016-06-08	中国药科大学	(s)-3-羟基吡咯烷盐酸盐的制备方法
GB201604647D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
KR102441327B1 (ko) *	2018-05-18	2022-09-07	주식회사유한양행	다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
JP2021535198A (ja)	2018-08-17	2021-12-16	ピーティーシーセラピューティクス，インコーポレイテッド	膵臓癌を治療する方法
CN118834204A (zh) *	2018-12-18	2024-10-25	阿斯利康(瑞典)有限公司	制药方法和中间体
CN110317176A (zh) *	2019-07-04	2019-10-11	沈阳药科大学	2-氨基嘧啶类化合物及其用途
KR20220006776A (ko) *	2020-07-09	2022-01-18	주식회사유한양행	다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4962115A (en)	1981-10-01	1990-10-09	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CZ284687B6 (cs)	1986-04-30	1999-02-17	Dainippon Pharmaceutical Co., Ltd.	Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
GB9005014D0 (en)	1990-03-06	1990-05-02	Janssen Pharmaceutica Nv	N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
HUT64023A (en)	1991-03-22	1993-11-29	Sandoz Ag	Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CN1142817A (zh) *	1993-10-12	1997-02-12	杜邦麦克制药有限公司	1n-烷基-n-芳基嘧啶胺及其衍生物
NZ274978A (en) *	1993-10-12	1998-04-27	Du Pont Merck Pharma	1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
IL112024A (en)	1993-12-21	1999-07-14	Novo Nordisk As	Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
ES2201112T3 (es)	1994-08-13	2004-03-16	Yuhan Corporation	Nuevos derivados de pirimidina y procedimientos para su preparacion.
US5739151A (en) *	1996-07-19	1998-04-14	Sepracor Inc.	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IN188411B (ko)	1997-03-27	2002-09-21	Yuhan Corp
US6825198B2 (en) *	2001-06-21	2004-11-30	Pfizer Inc	5-HT receptor ligands and uses thereof
DE602004019094D1 (de) *	2003-07-25	2009-03-05	Ciba Holding Inc	Pyrimidinen oder -chinazolinen als antimikrobielle mittel
US20050059704A1 (en) *	2003-08-29	2005-03-17	Dynogen Pharmaceuticals, Inc.	Compositions useful for treating gastrointestinal motility disorders
US20060057972A1 (en)	2004-09-14	2006-03-16	Wikel Harold L	Adapter for a modular wireless communication device
US20060128726A1 (en)	2004-11-24	2006-06-15	Xuebao Wang	Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
DK1856114T3 (en)	2005-02-25	2014-11-17	Raqualia Pharma Inc	Benzisoxazol-DERIVATIVES
US20070032514A1 (en) *	2005-07-01	2007-02-08	Zahn Stephan K	2,4-diamino-pyrimidines as aurora inhibitors
WO2007062417A1 (en) *	2005-11-28	2007-05-31	Kalypsys, Inc.	Methods of preparing 2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-yl-pyrimidine and 4-(1-alkylpyrrolidin-2-yl)-2-(1h-imidazol-1-yl)-6-methylpyrimidine derivatives
EP2003131A4 (en) *	2006-04-04	2009-12-16	Taisho Pharmaceutical Co Ltd	AMINOPYRROLIDINE COMPOUND
CA2648170A1 (en) *	2006-04-10	2007-10-18	Boehringer Ingelheim International Gmbh	2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
WO2008114378A1 (ja) *	2007-03-19	2008-09-25	Fujitsu Limited	データ処理装置、そのデータ監視方法、そのデータ監視プログラム、及びそのデータ監視プログラムを格納した記録媒体
MX2010008700A (es) *	2008-02-22	2010-08-30	Hoffmann La Roche	Moduladores de beta-amiloide.
ES2659725T3 (es) *	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
MX336155B (es) *	2011-02-25	2016-01-07	Yuhan Corp	Derivados de diaminopirimidina y procesos para su preparacion.

2012
- 2012-02-24 MX MX2013009627A patent/MX336155B/es unknown
- 2012-02-24 US US14/001,475 patent/US9850227B2/en active Active
- 2012-02-24 MX MX2013009549A patent/MX337477B/es active IP Right Grant
- 2012-02-24 JP JP2013555369A patent/JP5890436B2/ja active Active
- 2012-02-24 US US14/001,489 patent/US9890138B2/en active Active
- 2012-02-24 BR BR112013020641-1A patent/BR112013020641B1/pt active IP Right Grant
- 2012-02-24 AU AU2012221925A patent/AU2012221925B2/en active Active
- 2012-02-24 AU AU2012221927A patent/AU2012221927B2/en active Active
- 2012-02-24 KR KR1020120018933A patent/KR101671348B1/ko active IP Right Grant
- 2012-02-24 ES ES12749916.8T patent/ES2579830T3/es active Active
- 2012-02-24 CN CN201280010354.3A patent/CN103391935B/zh active Active
- 2012-02-24 EP EP12749916.8A patent/EP2678331B1/en active Active
- 2012-02-24 WO PCT/KR2012/001427 patent/WO2012115480A2/en active Application Filing
- 2012-02-24 PT PT127501146T patent/PT2678332T/pt unknown
- 2012-02-24 JP JP2013555368A patent/JP5980236B2/ja active Active
- 2012-02-24 RU RU2013142187/04A patent/RU2587493C2/ru active
- 2012-02-24 EP EP12750114.6A patent/EP2678332B1/en active Active
- 2012-02-24 IN IN1519MUN2013 patent/IN2013MN01519A/en unknown
- 2012-02-24 KR KR1020120018926A patent/KR101671341B1/ko active IP Right Grant
- 2012-02-24 PL PL12749916.8T patent/PL2678331T3/pl unknown
- 2012-02-24 BR BR112013019942-3A patent/BR112013019942B1/pt active IP Right Grant
- 2012-02-24 PL PL12750114.6T patent/PL2678332T3/pl unknown
- 2012-02-24 HU HUE12750114A patent/HUE029988T2/en unknown
- 2012-02-24 WO PCT/KR2012/001423 patent/WO2012115478A2/en active Application Filing
- 2012-02-24 CA CA2827030A patent/CA2827030C/en active Active
- 2012-02-24 CA CA2827072A patent/CA2827072C/en active Active
- 2012-02-24 CN CN201280010406.7A patent/CN103402997B/zh active Active
- 2012-02-24 DK DK12750114.6T patent/DK2678332T3/en active
- 2012-02-24 ES ES12750114.6T patent/ES2587304T3/es active Active
2014
- 2014-02-12 HK HK14101278.5A patent/HK1188214A1/zh unknown
- 2014-02-12 HK HK14101293.6A patent/HK1188215A1/xx unknown
2017
- 2017-11-15 US US15/813,741 patent/US10640490B2/en active Active
- 2017-12-20 US US15/848,760 patent/US10227330B2/en active Active

Also Published As

Publication number	Publication date
WO2012115480A3 (en)	2012-10-18
PL2678331T3 (pl)	2016-12-30
CN103402997B (zh)	2015-08-26
BR112013019942B1 (pt)	2022-01-11
RU2013142188A (ru)	2015-03-27
CA2827072A1 (en)	2012-08-30
MX336155B (es)	2016-01-07
RU2013142187A (ru)	2015-03-27
WO2012115478A2 (en)	2012-08-30
US20130331377A1 (en)	2013-12-12
EP2678332A4 (en)	2014-07-23
EP2678331A2 (en)	2014-01-01
PT2678332T (pt)	2016-08-22
US20180111918A1 (en)	2018-04-26
CN103391935B (zh)	2015-12-23
PL2678332T3 (pl)	2016-12-30
US20150274700A2 (en)	2015-10-01
HUE029988T2 (en)	2017-04-28
US10640490B2 (en)	2020-05-05
CA2827030A1 (en)	2012-08-30
BR112013020641B1 (pt)	2021-11-03
CA2827030C (en)	2019-01-08
AU2012221925B2 (en)	2016-05-05
CA2827072C (en)	2019-01-08
EP2678332B1 (en)	2016-05-18
EP2678331A4 (en)	2014-07-30
US20130338179A1 (en)	2013-12-19
US20180072705A1 (en)	2018-03-15
US10227330B2 (en)	2019-03-12
KR20120098483A (ko)	2012-09-05
WO2012115480A2 (en)	2012-08-30
BR112013019942A2 (pt)	2018-08-14
AU2012221927B2 (en)	2016-04-28
ES2587304T3 (es)	2016-10-21
KR101671341B1 (ko)	2016-11-01
KR101671348B1 (ko)	2016-11-01
DK2678332T3 (en)	2016-08-15
KR20120098484A (ko)	2012-09-05
RU2587493C2 (ru)	2016-06-20
ES2579830T3 (es)	2016-08-17
BR112013020641A2 (pt)	2016-10-18
HK1188214A1 (zh)	2014-04-25
JP5980236B2 (ja)	2016-08-31
US9850227B2 (en)	2017-12-26
US9890138B2 (en)	2018-02-13
JP2014506592A (ja)	2014-03-17
MX337477B (es)	2016-03-07
EP2678331B1 (en)	2016-04-27
CN103391935A (zh)	2013-11-13
CN103402997A (zh)	2013-11-20
HK1188215A1 (en)	2014-04-25
EP2678332A2 (en)	2014-01-01
MX2013009549A (es)	2013-09-06
WO2012115478A3 (en)	2012-10-18
JP2014506591A (ja)	2014-03-17
JP5890436B2 (ja)	2016-03-22
MX2013009627A (es)	2014-02-17

Publication	Publication Date	Title
IN2013MN01519A (ko)	2015-06-12
WO2012115479A3 (en)	2012-11-01	Diaminopyrimidine derivatives and processes for the preparation thereof
EA201270467A1 (ru)	2012-09-28	Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
CN112074519A8 (zh)	2021-05-11	作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂䓬-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
IL214572A (en)	2015-04-30	Annals of 9 - Alkylaryl - 9h - Furin - 6 - Converted Illamine, a Pharmaceutical Composition Containing Them and These Compounds That Are a Toll-like Colton Antagonist for the Treatment of Disease
WO2006104826A3 (en)	2007-03-01	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007111864A3 (en)	2008-10-02	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EA201290394A1 (ru)	2012-10-30	Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
WO2007136577A3 (en)	2008-01-10	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TNSN07313A1 (en)	2008-12-31	Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
DK1695710T3 (da)	2008-09-22	Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
HK1120442A1 (en)	2009-04-03	Novel opioid antagonists
CL2007003266A1 (es)	2008-07-04	Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
MX340234B (es)	2016-07-01	Tratamiento para transtornos gastrointestinales.
MX2014001798A (es)	2014-03-31	Tratamientos para trastornos gastrointestinales.
UA107334C2 (ru)	2014-12-25	Производные аминоэфиров алкалоидов и их лекарственные композиции
IL195514A (en)	2015-03-31	Converted Pyridyl Compounds
UA100877C2 (ru)	2013-02-11	Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3)
CL2011000061A1 (es)	2011-07-01	Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia.
WO2010031521A3 (en)	2011-02-24	Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders
WO2011045232A3 (en)	2011-06-16	Neuropeptide-2 receptor (y-2r) agonists
EP2238105A4 (en)	2012-02-22	NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH
EA201171271A1 (ru)	2012-05-30	Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида
WO2014016754A3 (en)	2014-03-13	Pharmaceutical compositions of proton pump inhibitor
UA112764C2 (uk)	2016-10-25	Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок